Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 56

1.

Randomized, Placebo-Controlled Trials in Alpha-1 Antitrypsin Deficiency.

Sandhaus RA.

Ann Am Thorac Soc. 2016 Aug;13 Suppl 4:S370-3. doi: 10.1513/AnnalsATS.201510-684KV.

PMID:
27564674
2.

Patient Involvement in the Design of a Patient-Centered Clinical Trial to Promote Adherence to Supplemental Oxygen Therapy in COPD.

Holm KE, Casaburi R, Cerreta S, Gussin HA, Husbands J, Porszasz J, Prieto-Centurion V, Sandhaus RA, Sullivan JL, Walsh LJ, Krishnan JA.

Patient. 2016 Jun;9(3):271-9. doi: 10.1007/s40271-015-0150-z.

PMID:
26521057
3.

Might your respiratory patient have alpha-1 antitrypsin deficiency?

Sandhaus RA, Knebel AR.

Heart Lung. 2015 Nov-Dec;44(6):463-4. doi: 10.1016/j.hrtlng.2015.07.003. No abstract available.

4.

Rationale and Design of the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis Study. Alpha-1 Protocol.

Strange C, Senior RM, Sciurba F, O'Neal S, Morris A, Wisniewski SR, Bowler R, Hochheiser HS, Becich MJ, Zhang Y, Leader JK, Methé BA, Kaminski N, Sandhaus RA; GRADS Alpha-1 Study Group..

Ann Am Thorac Soc. 2015 Oct;12(10):1551-60. doi: 10.1513/AnnalsATS.201503-143OC.

5.

Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.

Chapman KR, Burdon JG, Piitulainen E, Sandhaus RA, Seersholm N, Stocks JM, Stoel BC, Huang L, Yao Z, Edelman JM, McElvaney NG; RAPID Trial Study Group..

Lancet. 2015 Jul 25;386(9991):360-8. doi: 10.1016/S0140-6736(15)60860-1.

6.

The social environment and illness uncertainty in chronic obstructive pulmonary disease.

Hoth KF, Wamboldt FS, Ford DW, Sandhaus RA, Strange C, Bekelman DB, Holm KE.

Int J Behav Med. 2015 Apr;22(2):223-32. doi: 10.1007/s12529-014-9423-5.

7.

Circulating polymers in α1-antitrypsin deficiency.

Tan L, Dickens JA, Demeo DL, Miranda E, Perez J, Rashid ST, Day J, Ordoñez A, Marciniak SJ, Haq I, Barker AF, Campbell EJ, Eden E, McElvaney NG, Rennard SI, Sandhaus RA, Stocks JM, Stoller JK, Strange C, Turino G, Rouhani FN, Brantly M, Lomas DA.

Eur Respir J. 2014 May;43(5):1501-4. doi: 10.1183/09031936.00111213. No abstract available.

8.

Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression.

Mueller C, Chulay JD, Trapnell BC, Humphries M, Carey B, Sandhaus RA, McElvaney NG, Messina L, Tang Q, Rouhani FN, Campbell-Thompson M, Fu AD, Yachnis A, Knop DR, Ye GJ, Brantly M, Calcedo R, Somanathan S, Richman LP, Vonderheide RH, Hulme MA, Brusko TM, Wilson JM, Flotte TR.

J Clin Invest. 2013 Dec;123(12):5310-8. doi: 10.1172/JCI70314.

9.

Biochemical efficacy and safety of a new, ready-to-use, liquid alpha-1-proteinase inhibitor, GLASSIA (alpha1-proteinase inhibitor (human), intravenous).

Sandhaus RA, Stocks J, Rouhani FN, Brantly M, Strauss P.

COPD. 2014 Feb;11(1):17-25. doi: 10.3109/15412555.2013.804500.

PMID:
23822603
10.

Prospective impact of illness uncertainty on outcomes in chronic lung disease.

Hoth KF, Wamboldt FS, Strand M, Ford DW, Sandhaus RA, Strange C, Bekelman DB, Holm KE.

Health Psychol. 2013 Nov;32(11):1170-4. doi: 10.1037/a0032721.

11.

The impact of age on outcomes in chronic obstructive pulmonary disease differs by relationship status.

Holm KE, Plaufcan MR, Ford DW, Sandhaus RA, Strand M, Strange C, Wamboldt FS.

J Behav Med. 2014 Aug;37(4):654-63. doi: 10.1007/s10865-013-9516-7.

12.

The prospective association of perceived criticism with dyspnea in chronic lung disease.

Holm KE, Wamboldt FS, Ford DW, Sandhaus RA, Strand M, Strange C, Hoth KF.

J Psychosom Res. 2013 May;74(5):450-3. doi: 10.1016/j.jpsychores.2013.02.001.

13.

Differences in adjustment between individuals with alpha-1 antitrypsin deficiency (AATD)-associated COPD and non-AATD COPD.

Holm KE, Borson S, Sandhaus RA, Ford DW, Strange C, Bowler RP, Make BJ, Wamboldt FS.

COPD. 2013 Apr;10(2):226-34. doi: 10.3109/15412555.2012.719049.

14.

Neutrophil elastase-mediated lung disease.

Sandhaus RA, Turino G.

COPD. 2013 Mar;10 Suppl 1:60-3. doi: 10.3109/15412555.2013.764403. Review.

PMID:
23527919
15.

Introduction to the 50th anniversary of the description of alpha-1 antitrypsin deficiency.

Sandhaus RA, Stoller JK.

COPD. 2013 Mar;10 Suppl 1:1-2. doi: 10.3109/15412555.2013.765840. No abstract available.

PMID:
23527477
16.

Alcohol use predicts ER visits in individuals with alpha-1 antitrypsin deficiency (AATD) associated COPD.

Hoth KF, Ford DW, Sandhaus RA, Strange C, Wamboldt FS, Holm KE.

COPD. 2012 Aug;9(4):417-25. doi: 10.3109/15412555.2012.684414.

17.

Association of cigarette smoking and CRP levels with DNA methylation in α-1 antitrypsin deficiency.

Siedlinski M, Klanderman B, Sandhaus RA, Barker AF, Brantly ML, Eden E, McElvaney NG, Rennard SI, Stocks JM, Stoller JK, Strange C, Turino GM, Campbell EJ, Demeo DL.

Epigenetics. 2012 Jul;7(7):720-8. doi: 10.4161/epi.20319.

18.

The prevalence of alpha-1 antitrypsin deficiency among patients found to have airflow obstruction.

Rahaghi FF, Sandhaus RA, Brantly ML, Rouhani F, Campos MA, Strange C, Hogarth DK, Eden E, Stocks JM, Krowka MJ, Stoller JK.

COPD. 2012 Aug;9(4):352-8. doi: 10.3109/15412555.2012.669433. Erratum in: COPD. 2013 Aug;10(4):555. Brantly, Mark L [added]; Rouhani, Farshid [added]; Campos, Michael A [added].

PMID:
22506682
19.

Association of IREB2 and CHRNA3 polymorphisms with airflow obstruction in severe alpha-1 antitrypsin deficiency.

Kim WJ, Wood AM, Barker AF, Brantly ML, Campbell EJ, Eden E, McElvaney G, Rennard SI, Sandhaus RA, Stocks JM, Stoller JK, Strange C, Turino G, Silverman EK, Stockley RA, Demeo DL.

Respir Res. 2012 Feb 22;13:16. doi: 10.1186/1465-9921-13-16.

20.

Gene therapy meets stem cells.

Sandhaus RA.

N Engl J Med. 2012 Feb 9;366(6):567-9. doi: 10.1056/NEJMcibr1113400. No abstract available.

PMID:
22316453
Items per page

Supplemental Content

Loading ...
Support Center